Cargando…

Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease

IMPORTANCE: The EMERGE and ENGAGE phase 3 randomized clinical trials of aducanumab provide a robust data set to characterize amyloid-related imaging abnormalities (ARIA) that occur with treatment with aducanumab, an amyloid-β (Aβ)–targeting monoclonal antibody, in patients with mild cognitive impair...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salloway, Stephen, Chalkias, Spyros, Barkhof, Frederik, Burkett, Patrick, Barakos, Jerome, Purcell, Derk, Suhy, Joyce, Forrestal, Fiona, Tian, Ying, Umans, Kimberly, Wang, Guanfang, Singhal, Priya, Budd Haeberlein, Samantha, Smirnakis, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609465/ https://www.ncbi.nlm.nih.gov/pubmed/34807243 http://dx.doi.org/10.1001/jamaneurol.2021.4161

Ejemplares similares

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Comparing ARIA‐E severity scales and effects of treatment management thresholds
por: Klein, Gregory, et al.
Publicado: (2022)

Aducanumab: Appropriate Use Recommendations
por: Cummings, J., et al.
Publicado: (2021)

Alzheimer disease neuropathology in a patient previously treated with aducanumab
por: Plowey, Edward D., et al.
Publicado: (2022)

Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer’s Disease
por: Herring, William L., et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease
por: Carlson, Christopher, et al.
Publicado: (2016)

Validation of 3‐ and 5‐point severity scales to assess ARIA‐E
por: Bracoud, Luc, et al.
Publicado: (2023)

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque–removing agent, in patients with Alzheimer’s disease
por: Kandadi Muralidharan, Kumar, et al.
Publicado: (2021)

TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
por: Salloway, Stephen, et al.
Publicado: (2023)

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
por: Arndt, Joseph W., et al.
Publicado: (2018)

Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
por: Silvestro, Serena, et al.
Publicado: (2022)

Aducanumab for Alzheimer’s disease?
por: Walsh, Sebastian, et al.
Publicado: (2021)

Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
por: Lin, Lin, et al.
Publicado: (2022)

Aducanumab: What about the Patient?
por: Petersen, Ronald C.
Publicado: (2021)

Is Aducanumab for LMICs? Promises and Challenges
por: Gunawardena, Illangage P. C., et al.
Publicado: (2021)

Practical Considerations in the Administration of Aducanumab for the Neurologist
por: Coerver, Katherine, et al.
Publicado: (2022)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
por: Wojtunik-Kulesza, Karolina, et al.
Publicado: (2023)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2020)

Topical Insights Into the Post-Approval Controversies of Aducanumab
por: Kumar, Dhiraj, et al.
Publicado: (2021)

How Will Aducanumab Approval Impact AD Research?
por: Weiner, Michael W., et al.
Publicado: (2021)

Re: Aducanumab-Related ARIA: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2023)

Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis
por: Arrighi, H Michael, et al.
Publicado: (2016)

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
por: Shi, Mingchao, et al.
Publicado: (2022)

Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2023)

Aducanumab: evidence from clinical trial data and controversies
por: Tampi, Rajesh R, et al.
Publicado: (2021)

Estimated Annual Spending on Aducanumab in the US Medicare Program
por: Mafi, John N., et al.
Publicado: (2022)

Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
por: Vaz, Miguel, et al.
Publicado: (2022)

A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease
por: Leinenga, Gerhard, et al.
Publicado: (2021)

Should Canadian patients look forward to aducanumab for Alzheimer disease?
por: Watt, Jennifer A., et al.
Publicado: (2021)

Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
por: Lalli, Giovanna, et al.
Publicado: (2021)

Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review
por: Beshir, Semira Abdi, et al.
Publicado: (2022)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
por: Tolar, Martin, et al.
Publicado: (2020)

Aducanumab for Alzheimer’s disease: The never‐ending story that nurses should know
por: Petch, Joel, et al.
Publicado: (2021)

Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab
por: Chertkow, Howard, et al.
Publicado: (2021)

“Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey
por: Padovani, Alessandro, et al.
Publicado: (2021)

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
por: Söderberg, Linda, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3oeto60lo3ee4hj322cif0k3pi